Studies testing the efficacy of pravastatin (HMG-CoA reductase inhibitor), octreotide and pasireotide (somatostatin analogs, growth hormone, insulin, and glucagon inhibitors), bosutinib (Src/Bcr-Abl tyrosine kinase inhibitor), and tolvaptan (vasopressin V2 receptor antagonist; US Food and Drug Administration approved for the treatment of ADPKD) have all shown some consistency between clinical and preclinical trial results, demonstrating improvement in ADPKD phenotypes (Table 4). Here, HMGCR is linked to autosomal dominant polycystic kidney disease.